influenza vaccine (Radboud University Medical Center)

This drug entry refers to the use of a quadrivalent inactivated influenza vaccine (QIV) investigated by Radboud University Medical Center for its potential non-specific protective effects against COVID-19. The research, primarily conducted through the FLUMMR-BRA clinical trial in Brazil, explores the concept of "trained immunity." This mechanism involves the epigenetic and metabolic reprogramming of innate immune cells (such as monocytes and natural killer cells) following vaccination, which can lead to an enhanced, antigen-independent immune response against heterologous pathogens, including SARS-CoV-2. The study aims to determine if standard influenza vaccination can reduce the incidence and severity of COVID-19, providing a potential tool for pandemic preparedness and protection in populations with limited access to specific COVID-19 vaccines.

Other names

quadrivalent inactivated influenza vaccineQIVinfluenza vaccine-Radboud University Medical Center-COVID-19